Heart rate as a treatable cardiovascular risk factor

British Medical Bulletin

Volumn 90, Issue 1, 2009, Pages 71-84

  Tardif, Jean Claude ^a,b  

^a MONTREAL HEART INSTITUTE   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Cardiovascular disease; Coronary artery disease; Heart rate; Risk factors

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; IVABRADINE; NIFEDIPINE; PLACEBO; VERAPAMIL; ANTIHYPERTENSIVE AGENT; BENZAZEPINE DERIVATIVE;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ANGINA PECTORIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; ELECTROCARDIOGRAM; EXERCISE; HEART DEATH; HEART EJECTION FRACTION; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HEART OUTPUT; HEART RATE; HEART STROKE VOLUME; HUMAN; HYPERTENSION; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; STABLE ANGINA PECTORIS; SURVIVAL; TREATMENT OUTCOME; ADULT; DRUG EFFECT; EVIDENCE BASED MEDICINE; FEMALE; MALE; MIDDLE AGED; PRACTICE GUIDELINE; QUALITY OF LIFE; RISK FACTOR;

ADRENERGIC BETA-ANTAGONISTS; ADULT; ANTIHYPERTENSIVE AGENTS; BENZAZEPINES; CORONARY DISEASE; EVIDENCE-BASED MEDICINE; FEMALE; HEART RATE; HUMANS; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; QUALITY OF LIFE; RISK FACTORS;

EID: 70349571745     PISSN: 00071420     EISSN: 14718391     Source Type: Journal    
DOI: 10.1093/bmb/ldp016     Document Type: Review

References (42)

1. McGovern PG, Pankow JS, Shahar E et al. (1996) Recent trends in acute coronary heart disease-mortality, morbidity, medical care and risk factors. The Minnesota Heart Survey Investigators. N Engl J Med, 334, 884-890.
2. Steg PG, Bhatt DL, Wilson PW et al. (2007) One year cardiovascular event rates in outpatients with atherothrombosis. JAMA, 297, 1197-1206
3. Aboyans V, Criqui MH (2006). Can we improve cardiovascular risk prediction beyond risk equations in the physician's office? J Clin Epidemiol, 59, 547-558.
4. Fox K, Borer JS, Camm AJ et al. (2007) Resting heart rate in cardiovascular disease. J Am Coll Cardiol, 50, 823-830.
5. Lévy S, Guize L (2006) Heart rate, a major prognostic factor of cardiovascular risk. Therapie, 61, 115-119.
6. Palatini P (2007) Heart rate as an independent risk factor for cardiovascular disease: current evidence and basic mechanisms. Drugs, 67(Suppl 2), 3-13.
7. Dyer AR, Persky V, Stamler J et al. (1980) Heart rate as a prognostic factor for coronary heart disease and mortality: findings in three Chicago epidemiologic studies. Am J Epidemiol, 112, 736-749.
8. Kannel WB, Kannel CE, Paffenbarger R et al. (1987) Heart rate and cardiovascular mortality in the Framingham study. Am Heart J 113, 1489-1494.
9. Benetos A, Rudnichi A, Thomas F et al. (1999) Influence of heart rate on mortality in a French population: role of age, gender and blood pressure. Hypertension, 33, 44-52.
10. Seccareccia F, Pannozzo F, Dima F et al. (2001) Heart rate as a predictor of mortality: the MATISS project. Am J Public Health 91, 1258-1263.
11. Jouven X, Zureik M, Desnos M et al. (2001) Resting heart rate as a predictive risk factor for sudden cardiac death in middle-aged men. Cardiovasc Res, 50, 373-378.
12. Jouven X, Empana JP, Escolano S et al. (2009) Relation of heart rate at rest and long-term (.20 years) death rate in initially healthy middle-aged men. Am J Cardiol, 103, 279-283.
13. Gillman MW, Kannel WB, Belanger A et al. (1993) Influence of heart rate on mortality among persons with hypertension: the Framingham Study. Am Heart J, 125, 1148-1154.
14. Diaz A, Bourassa MG, Guertin MC et al. (2005) Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J, 26, 967-974.
15. Palatini P (2005) Heart rate: a strong predictor of mortality in subjects with coronary artery disease. Eur Heart J, 26, 943-945.
16. Hjalmarson A, Gilpin EA, Kjekshus J et al. (1990) Influence of heart rate on mortality after acute myocardial infarction. Am J Cardiol, 65, 547-553.
17. Zuanetti G, Mantini L, Hernández-Bernal F et al. (1998) Relevance of heart rate as a prognostic factor in patients with acute myocardial infarction: insights from the GISSI-2 study. Eur Heart J, Suppl F, F19-F26.
18. Disegni E, Goldbourt U, Reicher-Reiss H et al. (1995) The predictive value of admission heart rate on mortality in patients with acute myocardial infarction. J Clin Epidemiol, 48, 1197-1205.
19. Lechat P, Hulot JS, Escolano S et al. (2001) Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation, 103, 1428-1433. (Pubitemid 32220636)
20. Kolloch R, Legler UF, Champion A et al. (2008) Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST). Eur Heart J, 29, 1327-1334.
21. Dzau VJ, Antman EM, Black HR et al. (2006) The cardiovascular disease continuum validated: clinical evidence of improved outcome. Part I. Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation, 114, 2850-2870.
22. Dzau VJ, Antman EM, Black HR et al. (2006) The cardiovascular disease continuum validated: clinical evidence of improved outcome. Part II. Clinical trial evidence (Acute coronary syndromes through renal disease. Circulation, 114, 2871-2891.
23. Giannoglou GD, Chatzizisis YS, Zamboulis C et al. (2008) Elevated heart rate and atherosclerosis: an overview of the pathogenetic mechanisms. Int J Cardiol, 126, 302-312.
24. Kjekshus J (1986) Importance of heart rate in determining beta-blocker efficacy in acute and long-term myocardial infarction intervention trials. Am J Cardiol, 57, 43F-49F.
25. Cucherat M (2007) Quantitative relationship between resting heart rate reduction and magnitude of clinical benefits in post-myocardial infarction: a meta-regression of randomized clinical trials. Eur Heart J, 28, 3012-3019.
26. Flannery G, Gehrig-Mills R, Billah B et al. (2008) Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers. Am J Cardiol, 101, 865-869.
27. Hernandez AF, Hammill BG, O'Connor CM, Schulman KA, Curtis LH, Fonarow GC (2009) Clinical effectiveness of beta-blockers in heart failure. Findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure) Registry. J Am Coll Cardiol, 53, 184-192.
28. Bangalore S, Sawhney S, Messerli FH (2008) Relation of beta-blocker-induced heart rate lowering and cardioprotection in hypertension. J Am Coll Cardiol, 52, 1482-1489.
29. Di Francesco D, Camm AJ (2004) Heart rate lowering by specific and selective If current inhibition with ivabradine. Drugs, 64, 1757-1765.
30. Borer JS, Fox K, Jaillon P et al. (2003) Antianginal and antiischemic effects of ivabradine, an If inhibitor, in stable angina. A randomized, double blind, multicentered, placebo-controlled trial. Circulation, 107, 817-823.
31. Tardif JC, Ford I, Tendera M, Bourassa MG, Fox K (2005) Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J, 26, 2529-3236
32. Tardif JC, Ponikowski P, Kahan T for the ASSOCIATE study investigators (2009) Efficacy of the If current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4 month, randomized, placebo-controlled trial. Eur Heart J, 30, 540-548.
33. Mulder P, Barbier S, Chagraoui A et al. (2004) Long-term heart rate reduction induced by the selective If current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. Circulation, 109, 1674-1679.
34. Custodis F, Baumahakel M, Schlimmer N et al. (2008) Heart rate reduction with ivabradine reduces oxidative stress, improves endothelial function and prevents atherosclerosis in apoli-poprotein E deficient mice. Circulation, 117, 2377.
35. Fox K, Ford I, Steg PG et al. (2008) Ivabradine for patients with stable coronary artery disease and left ventricular dysfunction (Beautiful): a randomized, double-blind, placebo-controlled trial. Lancet, 372, 807-816.
36. Fox K, Ford I, Steg PG et al. (2008) Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet, 6, 372, 817-821.
37. Palatini P, Benetos A, Grassi G et al. (2006) Identification and management of the hypertensive patient with elevated heart rate: statement of a European Society of Hypertension Consensus Meeting. J Hypertens, 24, 603-610.
38. Guidelines for the management of arterial hypertension (2007) The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens, 25, 1105-1187.
39. Erikssen J, Rodahl K (1979) Resting heart rate in apparently healthy middle-aged men. Eur J Appl Physiol, 42, 61-69.
40. Aronow WS, Ahn C, Mercando AD, Epstein S (1996). Association of average heart rate on 24-hour ambulatory electrocardiograms with incidence of new coronary events at 48-month follow-up in 1311 patients (mean age 81 years) with heart disease and sinus rhythm. Am J Cardiol, 78, 1175-1176.
41. Hozawa A, Ohkubo T, Kikuya M et al. (2004) Prognostic value of home heart rate for cardiovascular mortality in the general population: the Ohasama study. Am J Hypertens, 17, 1005-1010.
42. Graham I, Atar D, Borch-Johnsen K et al. (2007) European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J, 28, 2375-2414.